AU2003242895A1 - Combination of PDE5 inhibitors with angiotensin II receptor antagonists - Google Patents

Combination of PDE5 inhibitors with angiotensin II receptor antagonists Download PDF

Info

Publication number
AU2003242895A1
AU2003242895A1 AU2003242895A AU2003242895A AU2003242895A1 AU 2003242895 A1 AU2003242895 A1 AU 2003242895A1 AU 2003242895 A AU2003242895 A AU 2003242895A AU 2003242895 A AU2003242895 A AU 2003242895A AU 2003242895 A1 AU2003242895 A1 AU 2003242895A1
Authority
AU
Australia
Prior art keywords
pde5
angiotensin
methyl
inhibitor
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003242895A
Other languages
English (en)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2003242895A1 publication Critical patent/AU2003242895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003242895A 2002-06-26 2003-06-16 Combination of PDE5 inhibitors with angiotensin II receptor antagonists Abandoned AU2003242895A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination
GB0214784.1 2002-06-26
PCT/IB2003/002657 WO2004002461A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Publications (1)

Publication Number Publication Date
AU2003242895A1 true AU2003242895A1 (en) 2004-01-19

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003242895A Abandoned AU2003242895A1 (en) 2002-06-26 2003-06-16 Combination of PDE5 inhibitors with angiotensin II receptor antagonists

Country Status (20)

Country Link
EP (1) EP1524996A2 (https=)
JP (1) JP2005531627A (https=)
KR (1) KR20050013156A (https=)
CN (1) CN1662257A (https=)
AR (1) AR040337A1 (https=)
AU (1) AU2003242895A1 (https=)
BR (1) BR0312030A (https=)
CA (1) CA2491002A1 (https=)
GB (1) GB0214784D0 (https=)
GT (1) GT200300124A (https=)
MX (1) MXPA04012569A (https=)
NO (1) NO20050400L (https=)
PA (1) PA8575501A1 (https=)
PE (1) PE20040868A1 (https=)
PL (1) PL375079A1 (https=)
RU (1) RU2004136276A (https=)
TW (1) TW200404546A (https=)
UY (1) UY27863A1 (https=)
WO (1) WO2004002461A2 (https=)
ZA (1) ZA200409532B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
EP2433555A3 (en) * 2002-07-26 2013-01-16 Olympus Corporation Image processing system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
ES2376628T3 (es) 2005-06-10 2012-03-15 Dong-A Pharmaceutical Co., Ltd. Agente para la prevención y el tratamiento de las enfermedades hep�?ticas que contiene un dirivado pirazolopirimidina.
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
EP1940389A2 (en) * 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2345763C1 (ru) * 2007-04-26 2009-02-10 ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6362178B1 (en) * 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Also Published As

Publication number Publication date
ZA200409532B (en) 2006-06-28
CN1662257A (zh) 2005-08-31
PE20040868A1 (es) 2004-11-25
MXPA04012569A (es) 2005-04-19
RU2004136276A (ru) 2005-09-10
KR20050013156A (ko) 2005-02-02
JP2005531627A (ja) 2005-10-20
BR0312030A (pt) 2005-03-22
AR040337A1 (es) 2005-03-30
GT200300124A (es) 2004-03-17
NO20050400L (no) 2005-03-29
WO2004002461A3 (en) 2004-05-13
GB0214784D0 (en) 2002-08-07
EP1524996A2 (en) 2005-04-27
PL375079A1 (en) 2005-11-14
PA8575501A1 (es) 2003-12-30
UY27863A1 (es) 2003-12-31
WO2004002461A2 (en) 2004-01-08
TW200404546A (en) 2004-04-01
CA2491002A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
JP2004506009A (ja) インスリン抵抗性症候群の治療
US20040186046A1 (en) Treatment of type 1 diabetes with PDE5 inhibitors
HUE028008T2 (en) sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
MXPA04007430A (es) Uso de inhibidores de pde5 en el tratamiento de cicatrices y fibrosis.
WO2002019213A2 (en) Method for treatment of migraine using pde5 inhibitors
AU2003223071A1 (en) Pharmaceutical combination of PDE5 inhibitors with ACE inhibitors
AU2003242895A1 (en) Combination of PDE5 inhibitors with angiotensin II receptor antagonists
AU2005274546B2 (en) Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
US20040132731A1 (en) Novel combination
US20040077624A1 (en) Novel combination
JP2006520777A (ja) Ｐｄｅ５阻害剤を用いる１型糖尿病の治療
WO2005011727A1 (en) Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder
WO2005042022A2 (en) Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
KR100595807B1 (ko) 조루 치료법
US20050059660A1 (en) Novel combination
HK1077219A (en) Combination of pde5 inhibitors with angiotensin ii receptor antagonists
US20040224962A1 (en) Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
HK1076380A (en) Pharmaceutical combination of pde5 inhibitors with ace inhibitors
JP4904268B2 (ja) 低色素性障害を治療・予防するためのｐｄｅ５阻害剤、異性体、塩の使用

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period